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It has been estimated that this syndrome affects 7% of adults with asthma and 14% of those who have severe asthma. 2 Pathologically, AERD is characterized by marked eosinophilic inflammation and ongoing mast-cell activation in the respiratory mucosa. The frequent recurrence of nasal polyps after surgery, as well as the requirement for high-dose glucocorticoids to manage the asthma, reflect the aggressive, persistent nature of the disease. The typical onset is in adulthood, with or without preexisting asthma, rhinitis, or atopy. 3 An absence of familial clustering argues against a strong genetic basis, and the identification of variants of candidate genes in small studies has not been replicated. 4 All nonsteroidal antiinflammatory drugs (NSAIDs) that inhibit both cyclooxygenase (COX)-1 and COX-2 may provoke the pathognomonic reactions in AERD; these reactions are accompanied by idiosyncratic activation of respiratory tract mast cells. In contrast, patients with AERD can usually be treated with COX-2-selective drugs without having these reactions. 5 The fact that structurally diverse NSAIDs that block COX-1 all provoke reactions reflects an enigmatic requirement for COX-1-derived prostaglandins to maintain a tenuous homeostasis. Curiously, the reactions also induce a refractory state in which NSAIDs can be used with diminished or no sequelae (desensitization); in fact, after desensitization, high-dose aspirin has therapeutic benefits. 6 Insights into the mechanisms responsible for the pathogenesis of AERD or its treatment have been limited. Dysregulated function of the 5-lipoxygenaseleukotriene C 4 (LTC 4 ) synthase pathway, which converts arachidonic acid to the cysteinyl leukotrienes, is a hallmark of AERD. Cysteinyl leukotrienes potently induce bronchoconstriction, vascular leak, and mucous secretion; they also amplify eosinophilic inflammation. The levels of leukotriene E 4 (LTE 4 ), the stable end metabolite of the cysteinyl leukotrienes, in urine from patients with AERD exceed those in urine from controls with asthma who are able to take aspirin, and they increase markedly during NSAIDinduced reactions. 7 Both zileuton, which blocks 5-lipoxygenase activity, and drugs that selectively block the type 1 receptor for the cysteinyl leukotrienes attenuate the bronchoconstriction induced by aspirin challenges 8, 9 and can improve sinonasal function and the control of asthma symptoms.
10,11 NSAID-induced increases in LTE 4 during clinical reactions are paralleled by increases in the products of activated mast cells (histamine, tryptase, and prostaglandin D 2 [PGD 2 ]) and are blocked by the administration of mast-cellstabilizing drugs. 12 Thus, mast-cell activation contributes substantially to cysteinyl leukotriene formation when COX-1 is inhibited in AERD. Additional cells probably contribute to the baseline production of cysteinyl leukotrienes. One study reported strong eosinophil-specific overexpression of LTC 4 synthase in bronchial biopsy specimens from patients with AERD, as compared with aspirin-tolerant controls. 13 Both the blood and sinonasal tissues of patients with AERD contain aberrantly large numbers of platelet-adherent neutrophils, monocytes, and eosinophils. Platelets express LTC 4 synthase, and this study estimated that they contribute approximately 70% of cysteinyl leukotriene formation by adhering to 5-lipoxygenase-expressing granulocytes and driving LTC 4 synthesis through transcellular transfer of metabolic intermediates. 14 The numbers of platelet-adherent granulocytes in the blood were strongly correlated with basal levels of LTE 4 in urine. Depletion of plateletadherent granulocytes in a recent study of a mouse model of AERD was found to markedly attenuate cysteinyl leukotriene formation and NSAID-induced changes in lung function. 15 Collectively, these studies suggest that the mechanism or mechanisms accounting for dysregulation of the 5-lipoxygenase-LTC 4 synthase pathway is fundamental to AERD pathogenesis and that this dysregulation is manifested across several effector-cell types.
What accounts for the dependency on COX-1 for the maintenance of homeostasis over cysteinyl leukotriene synthesis and mast-cell activation in AERD? Several lines of evidence suggest that prostaglandin E 2 (PGE 2 ), a ubiquitous COX pathway product, maintains a critical "check" against 5-lipoxygenase activity and mast-cell activation. PGE 2 synthesis characteristically increases with inflammation, as a result of up-regulated expression of COX-2 and microsomal PGE 2 synthase 1 in several cell types. 16 Studies of nasal polyp fibroblasts suggest that this up-regulation may be locally impaired in the respiratory tissues of patients with AERD. 17 A potential consequence is that ongoing production of PGE 2 in AERD may depend disproportionately on COX-1 and thus be especially susceptible to depletion by nonselective NSAIDs. PGE 2 signaling through E prostanoid 2 receptors prevents mast-cell activation, 18, 19 inhibits 5-lipoxygenase function, 20 and inhibits platelet activation. 21 Inhalation of aerosols of PGE 2 by persons with AERD blocks aspirin-induced changes in lung function and in urinary LTE 4 levels. 22 Expression of E prostanoid 2 receptor by mast cells, eosinophils, neutrophils, and T cells infiltrating the respiratory mucosa of persons with AERD is diminished as compared with that in controls. 23 Collectively, these studies suggest that a spectrum of abnormalities in inducible COX-2-dependent PGE 2 production and E prostanoid 2 receptor expression, potentially due to subtle genetic or epigenetic functional perturbations, 24 could compromise homeostasis to permit exaggerated cysteinyl leukotriene production, with activation of platelets and mast cells in patients with aspirin sensitivity. This is supported by the observation that an AERD-like phenotype develops when pulmonary inflammation is induced experimentally in mice that are selectively deficient in microsomal PGE 2 synthase 1 or E prostanoid 2 receptors. 15 If PGE 2 is critical to homeostasis, what accounts for the idiosyncratic activation of mast cells and the severe, recalcitrant eosinophilic inflammation of AERD? Interleukin-33 and thymic stromal lymphopoietin (TSLP) are cytokines derived from structural cells that provide a first response to environmental proteases, helminths, and viruses. 25 In experimental models, administration of interleukin-33 and TSLP can induce eosinophil-rich pathologic changes (innate type 2 immunity) by acting directly on lymphoid and myeloid effector cells, including mast cells. Recent studies demonstrate that both interleukin-33 and TSLP are expressed strongly by nasal polyp tissue from persons with AERD. 26, 27 Nasal polyp TSLP messenger RNA (mRNA) expression in AERD correlates with the expression of mast-cell markers in the same samples. In a mouse model of AERD, blockade of interleukin-33 or its receptor completely prevents aspirin-induced changes in lung function and release of mast-cell mediators. 26 In this model, deletion of Ltc4s, the gene encoding the pivotal enzyme in cysteinyl leukotriene synthesis, attenuates interleukin-33 expression and eosinophilic inflammation. These studies suggest that mast-cell activation and eosinophilic inflammation in AERD may reflect persistent cysteinyl leukotriene-mediated amplification of the innate type 2 immune system (Fig. 1) . It is possible that mast cells convey responses from the upstream cytokines (interleukin-33 and TSLP) to downstream effector cells through elaboration of soluble mediators in AERD.
One such mediator, PGD 2 , is generated at particularly high levels in persons with AERD at baseline and (especially) during reactions. PGD 2 is a potent chemotactic factor and activating ligand for eosinophils, basophils, and lymphoid helper cells acting through chemoattractant receptor homologue expressed by type 2 helper T cells (CRTH2), 28 and it elicits broncho-constriction through T prostanoid receptors. which probably reflects their recruitment to the tissue. 27 It is notable that the clinical benefits of high-dose aspirin occur concomitantly with sharply reduced levels of PGD 2 metabolites in urine and increases in blood eosinophils, potentially reflecting a loss of the PGD 2 chemotactic gradient. 29 The AERD puzzle is not solved. The inciting cause or causes are yet to be determined, and the contributions of potential epigenetic or environmental factors to disease pathogenesis are largely unknown. Nonetheless, the evolving knowledge base suggests potential for therapeutic strategies. Clinical trials are under way to determine the therapeutic efficacy of prasugrel, an antiplatelet drug, in blocking transcellular cysteinyl leukotriene synthesis, as well as that of ifetroban, a T prostanoid receptor antagonist, in the treatment of patients with AERD (ClinicalTrials.gov numbers NCT01597375 and NCT02216357, respectively). Future therapeutic targets could include antagonists of CRTH2, blockers of interleukin-33 and TSLP, monoclonal antibodies against interleukin-5 or interleukin-5 receptor that deplete tissue eosinophils, and stable mimics of protective eicosanoids (PGE 2 and lipoxins 30 ). The results of trials with such agents will also undoubtedly reveal additional insights into the mechanisms underlying this disease.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. In Panel A, insufficient function of the inducible cyclooxygenase (COX)-2-microsomal prostaglandin E 2 synthase 1 (mPGES-1)-dependent system of prostaglandin E 2 production facilitates persistent synthesis of leukotriene C 4 (LTC 4 ) by effector cells expressing 5-lipoxygenase-LTC 4 synthase (including LTC 4 synthase-expressing platelets adherent to 5-lipoxygenase-expressing granulocytes). The structural cell-derived cytokines interleukin-33 and thymic stromal lymphopoietin (TSLP) promote ongoing inflammation and release of mastcell products, including prostaglandin D 2 . In Panel B, the administration of aspirin or other nonselective nonsteroidal antiinflammatory drugs depletes the residual prostaglandin E 2 , permitting strong 5-lipoxygenase activation and further generation of LTC 4 . Cysteinyl leukotrienes induce the release of interleukin-33 and consequent mast-cell activation, with bronchoconstriction occurring as a result of the direct effects of cysteinyl leukotrienes, prostaglandin D 2 , and other mast cellderived products. Prostaglandin D 2 recruits effector cells expressing chemoattractant receptor homologue expressed by type 2 helper T (Th2) cells (CRTH2) to the respiratory tissue and induces bronchoconstriction through T prostanoid receptors. LTD 4 denotes leukotriene D 4 , LTE 4 leukotriene E 4 , and ST2 suppression of tumorigenicity 2.
